Seattle Genetics traded at $179.33 this Friday June 24th, increasing $5.33 or 3.06 percent since the previous trading session. Looking back, over the last four weeks, Seattle Genetics gained 31.41 percent. Over the last 12 months, its price rose by 14.09 percent. Looking ahead, we forecast Seattle Genetics to be priced at 174.51 by the end of this quarter and at 160.80 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
179.33
Daily Change
3.06%
Yearly
14.09%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,743.00 36.00 0.97% -0.40%
Astellas Pharma 2,151.00 -27.00 -1.24% 7.04%
Eisai 5,607.00 46.00 0.83% -52.34%
Daiichi Sankyo 3,325.00 13.00 0.39% 35.99%
AbbVie 152.34 2.89 1.93% 34.84%
Acadia Pharmaceuticals 14.98 0.26 1.77% -42.76%
Agios Pharmaceuticals 22.57 1.29 6.06% -60.21%
Amgen 245.37 2.28 0.94% 1.11%
Bayer 57.79 -0.75 -1.28% 11.59%
Biogen 211.93 0.55 0.26% -39.09%
Bluebird Bio 4.40 0.12 2.80% -85.77%
BioMarin Pharmaceutical 86.85 2.30 2.72% 2.43%
Bristol-Myers Squibb 78.96 1.27 1.63% 18.31%
Celldex Therapeutics 29.35 3.21 12.28% -9.72%
Clovis Oncology 1.70 -0.04 -2.30% -74.01%
Esperion Therapeutics 6.47 0.18 2.86% -72.68%
Exelixis 22.22 0.89 4.17% -5.12%
Genmab 2,232.00 69.00 3.19% -14.48%
Gilead Sciences 63.08 0.50 0.80% -7.07%
GlaxoSmithKline 1,756.20 36.60 2.13% 24.27%
Glaxosmithkline 43.69 0.94 2.20% 9.83%
Immunogen 4.31 -0.06 -1.37% -38.07%
Incyte Corp 78.19 3.41 4.56% -9.95%
Insmed 21.42 1.57 7.91% -25.98%
Karyopharm Therapeutics 5.17 0.04 0.78% -52.96%
Eli Lilly 325.62 12.90 4.13% 41.44%
MacroGenics 3.34 0.01 0.30% -87.71%
Merck & Co 93.13 1.13 1.23% 20.63%
Moderna Inc 144.27 1.01 0.71% -34.40%
Mirati Therapeutics 68.16 2.27 3.45% -58.51%
Nektar Therapeutics 4.03 -0.13 -3.13% -76.66%
Novartis 80.60 2.37 3.03% -4.80%
Puma Biotechnology 2.85 -0.05 -1.72% -70.41%
Pfizer 51.59 1.50 2.99% 32.35%
Regeneron Pharmaceuticals 612.49 5.10 0.84% 11.25%
Sanofi 100.56 4.81 5.02% 13.95%
Seattle Genetics 179.33 5.33 3.06% 14.09%
Spectrum Pharmaceuticals 0.88 -0.01 -1.18% -77.38%
Sarepta Therapeutics 75.22 3.40 4.73% -6.44%
Teva Pharmaceutical Industries Ltd 2,689.00 12.00 0.45% -20.84%
Vertex Pharmaceuticals 292.55 9.05 3.19% 50.54%
Xencor 27.12 0.54 2.03% -25.29%

Indexes Price Day Year
USND 11608 375.43 3.34% -19.17%

Seattle Genetics
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.